Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand.
It takes 30 seconds or login using your email address
Please enter the email address that you registered the newsletter with